Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

MS-Japan June 2026 Rebalance: Pre-Implementation Update

MS-Japan June 2026 Rebalance: Post-Implementation Review

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>We analyzed the post-announcement return pattern of MS-Japan rebalance stocks in the context of past MSCI Japan cycles.</li>
<li>DELETE: 14 names averaged -5.3% WPreA alpha before announcement; all 14 negative; flat on WAI Day 1. </li>
<li>ADD: All three stocks ran +18-21% WPreA alpha before announcement. WAI Day 1 returns split by velocity group. Historical ADD WAI alpha is mixed across prior cycles.</li>
</ul>


We analyzed the post-announcement return pattern of MS-Japan rebalance stocks in the context of past MSCI Japan cycles.
DELETE: 14 names averaged -5.3% WPreA alpha before announcement; all 14 negative; flat on WAI Day 1. 
ADD: All three stocks ran +18-21% WPreA alpha before announcement. WAI Day 1 returns split by velocity group. Historical ADD WAI alpha is mixed across prior cycles.


MS-Japan May 2026 Rebalance: Post-Announcement Trading Pattern

M3 Inc

MS-Japan May 2026 Rebalance: Post-Announcement Trading Pattern